


19th International Fritz-Bender Foundation Symposium on CANCER BIOLOGY FOR CANCER THERAPEUTICS

jointly with the

10th Annual Scientific Conference of the Istituto Toscano Tumori (ITT)



1-3 July 2015
Auditorium of CNR, Pisa

July 1, 2015

8:30 – Registration

9:00 – Welcome (Luzzatto, Huber, Mihich)

Session I.

The Path from Normal Cell to Cancer Cell

9:30 - Sean Grimmond (Glasgow): *The somatic mutation landscape of human cancer*

10:10 - Manel Esteller (Madrid): *Cancer Epigenetics: from knowledge to applications*

10:50 - Break

11:10 - John Pawelek (New Haven): *Macrophage-cancer cell fusion as a mechanism of metastasis*

11:50 - Francesca Demichelis (Trento): *Driver clones during prostate cancer evolution*

12:30 - Jacopo Petrini (Pisa): *Genomic characterization of thymic epithelial tumors*

12:50 - Silvo Conticello (Firenze): *DNA editing by AID/APOBECs in human cancer*

13:10 - Break

Keynote Lecture:

14:00 - Bob Weinberg (Boston): *Cancer stem cells, EMT and malignant progression*

Session II.

Targeting the Tumor, Targeting the environment

15:10 - Ross Levine (New York): *Genetics and therapy of acute myeloid leukemia*

15:50 - Alessandro Vannucchi (Firenze): *New treatments for myeloproliferative neoplasms*

16:30 - Break

16:50 - Maria Sibilia (Vienna): *EGFR signaling networks in cancer development*

17:30 - Neal Rosen (New York): *Mechanisms-based strategies for combining target therapies*

18:10 - Laura Poliseno (Pisa): *ERK-pathway regulated microRNAs in melanoma*

July 2, 2015

Session III.

The Cancer Cell, the Tumor, and the Host

09:00 - Soldano Ferrone (Harvard): *Combinatorial immunotherapy eradicates both differentiated cancer cells and cancer initiating cells*

09:40 - Zena Werb (San Francisco): *The role of microenvironment in cancer progression, metastasis and response to therapy*

10:20 - Tadatsugu Taniguchi (Tokyo): *Recognition of self-derived molecular inflammation and antitumor immunity*

11:00 - Break

11:20 - Raffaella Giavazzi (Milano): *Profiling response to treatments with angiogenesis inhibitors in ovarian cancer*

12:00 - Valeria Santini (Firenze): *Efforts to unravel the molecular mechanisms of myelodysplastic syndromes in 2015*

12:20 - Giannino Del Sal (Trieste): *Mutant p53 liaisons in Breast Cancer*

13:00 - Break

Session IV.

Development of new Therapies

14:30 - Alex Matter (Singapore): *Innovation in cancer medicine in Singapore through translational R&D of the public sector*

15:10 - Sarah Martin (London): *Synthetic lethality as a novel therapeutic strategy*

15:50 - Thomas Dittmar (Witten): *Cell fusion and cancer progression: implications for therapeutic intervention strategies*

16:30 - Break

16:50 - Michel Sadelain (New York): *CAR therapy: the CD19 paradigm*

17:30 - Kurt Zanker (Witten): *Concluding remarks*

July 3, 2015

Session V.

**Research Progress Reports and Clinical Case Discussions
by Members of Istituto Toscano Tumori**

9:30-13:10 - Part I (*detailed program on www.ittumori.it*)

Bender Lecture:

14:00 - Pier Paolo Pandolfi (Boston): *The non-coding RNA revolution in cancer research and therapy*

15:00-16:30 - Part II (*detailed program on www.ittumori.it*)

Symposium Co-Chairs:

Lucio Luzzatto, Istituto Toscano Tumori (Italy)

Kurt S. Zaenker, Fritz Bender Foundation & University of Witten/Herdecke (Germany)

Enrico Mihich, Dana Farber Cancer Institute (USA)

The program has been organized by Silvo Conticello, Lucio Luzzatto, Rosario Notaro, and Enrico Mihich (Chairman)

For information and registration:

AD HOC Eventi - 055 4480891; info@adhoc-eventi.it